We previously showed that presence of a baseline IFN signature in patients with MS is related to non-responsiveness to IFNβ treatment [27] and it is highly relevant to further investigate the role of GC-A and GC-B in this perspective, which is the objective of future studies. The gene discussed is IFNB1; the disease is myeloid sarcoma.